Endo International PLC (NASDAQ:ENDP)’s share price was down 3.7% during mid-day trading on Monday . The stock traded as low as $23.05 and last traded at $23.28, with a volume of 4,773,342 shares trading hands. The stock had previously closed at $24.18.

Several equities analysts recently issued reports on ENDP shares. Morgan Stanley reissued a “hold” rating and set a $15.00 price objective (down from $50.00) on shares of Endo International PLC in a report on Thursday, May 12th. Royal Bank Of Canada reissued a “sector perform” rating and set a $26.00 price objective on shares of Endo International PLC in a report on Wednesday, May 18th. Leerink Swann lowered shares of Endo International PLC from an “outperform” rating to a “market perform” rating and set a $23.00 price objective on the stock. in a report on Friday, May 6th. Barclays PLC cut their price objective on shares of Endo International PLC from $37.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, May 6th. Finally, Vetr lowered shares of Endo International PLC from a “strong-buy” rating to a “buy” rating and set a $18.57 price objective on the stock. in a report on Tuesday, August 2nd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $39.78.

The stock’s market capitalization is $5.11 billion. The firm’s 50-day moving average price is $18.33 and its 200-day moving average price is $27.08.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.86 EPS for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.12. The firm earned $921 million during the quarter, compared to analysts’ expectations of $873.50 million. The company’s revenue for the quarter was up 25.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.08 earnings per share. Equities analysts expect that Endo International PLC will post $4.56 EPS for the current fiscal year.

Several hedge funds and institutional investors recently bought and sold shares of ENDP. Advantus Capital Management Inc increased its position in Endo International PLC by 2.4% in the fourth quarter. Advantus Capital Management Inc now owns 19,971 shares of the company’s stock worth $1,223,000 after buying an additional 476 shares during the period. BNP Paribas Arbitrage SA boosted its stake in shares of Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock worth $16,737,000 after buying an additional 12,234 shares in the last quarter. American International Group Inc. boosted its stake in shares of Endo International PLC by 21.8% in the fourth quarter. American International Group Inc. now owns 99,335 shares of the company’s stock worth $6,081,000 after buying an additional 17,770 shares in the last quarter. Finally, RS Investment Management Co. LLC boosted its stake in shares of Endo International PLC by 29.5% in the fourth quarter. RS Investment Management Co. LLC now owns 543,593 shares of the company’s stock worth $33,279,000 after buying an additional 123,692 shares in the last quarter.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.